🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We had so much fun at Generate:Biomedicines bring your child to work day! Thank you to all of the Generators who planned and executed such a thoughtful and entertaining event for our families. #TeamGenerate

Today we announced that we raised $273 million in Series C financing to advance our preclinical & clinical pipeline. We’re proud to have the confidence of our investors, including all Series B investors, who believe we are revolutionizing drug development: bit.ly/3rffQ0q

Today we release Chroma, our generative model for protein design, open-source on Github with a Nature publication describing its biophysical and crystallographic validation. Chroma Conditioners enable one model to target multiple protein design objectives. generatebiomedicines.com/chroma

A monumental work by John Ingraham and team Generate:Biomedicines on Chroma✨ for protein design. Congrats!!! 🔥🎉🔥🎉 So excited to see it out, fully open source and with experimentally validated xtal structures! Perhaps cryo-EM of the giant complexes next? generatebiomedicines.com/chroma

Congratulations Generate:Biomedicines! This is an exciting moment to share a glimpse of the amazing science being done by the team from the foundations of Chroma to testing and learning in the lab - and ultimately developing novel medicines. Just look at those beautiful proteins!

Those are some beautiful proteins Generate:Biomedicines !

This year, Flagship Pioneering and our companies took #BiggerLeaps to pioneer advances to help patients and the planet. Looking forward to what’s ahead in 2024. #WeAreFlagship

We’re thrilled to be featured in this week’s episode of 60 Minutes on CBS, which explores NVIDIA’s pioneering role in AI and our mutual commitment to transforming human health. Tune in to discover how AI is revolutionizing drug development and more. youtube.com/watch?v=vE8Rw0…

Researchers are using AI to create new proteins that do not exist in nature to fight diseases like cancer and asthma. cbsn.ws/3Qp03FL

We’re thrilled to have been named to the 2024 CNBC Disruptors 50 list, ranking at #25. Alongside OpenAI & ElevateBio, we are proud to be recognized for our pioneering efforts in shaping the future of medicine. Learn more about our recognition: cnbc.com/2024/05/14/gen…

So grateful that Andrew Beam decided to take this crazy leap to team up again to transform all aspects of how we do science with AI! Building companies with big missions is never a straight line- there will be ups, there will be downs- and it’s all about the people by your

How do AI & drug development expertise reshape what’s possible? In a multi-target collaboration potentially valued at over $1 billion, we are partnering with Novartis to develop novel protein therapeutics that address critical medical needs. Learn more: generatebiomedicines.com/news/generateb…

We Lila Sciences are excited to come out of stealth! Join us at #NeurIPS2024 for a happy hour co-hosted with NVIDIA, featuring a discussion on AI in science with Max Welling and Chris Bishop. If you’ll be at NeurIPS this year, we’d love to see you! RSVP below 👇

Excited to take our first steps out of stealth! 🚀 Introducing Lila Sciences, one of our newest companies at Flagship Pioneering building AI for scientific discovery. Join us at #NeurIPS2024 for a happy hour co-hosted with NVIDIA , featuring a discussion on AI in Science with

We are Lila Sciences, a company pursuing scientific superintelligence to solve humankind's greatest challenges. Learn more: lila.ai

.Lila Sciences had a great time at #NeurIPS2024 . Thanks to everyone who came out to our event last night- it was a blast to meet you all and share a bit more about what we’ve been up to! Glad you all enjoyed the drink names as much as we enjoyed coming up with them!

Missed it the first time? This Sunday, 60 Minutes will re-air its segment on NVIDIA's groundbreaking role in AI. The episode explores how their innovations in computing power are transforming industries—including drug discovery. Alexandra Snyder, MD, our EVP of R&D, shares how

Today I am thinking of the people I’ve met around the world—children, parents, health workers, teachers—who will be harmed by the Trump administration’s decision to try to dismantle USAID and walk back U.S. leadership in global health and poverty reduction. I’m thinking, too,

GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted